IceCure Medical (ICCM)

Its main platform, marketed under the ProSense name, is designed to create controlled ice formations inside a tumour while surrounding tissue is monitored with imaging tools such as ultrasound or CT. The procedure can often be performed through a small incision, which may reduce scarring, recovery time and the need for more invasive intervention. IceCure has positioned the technology for use across multiple tumour types, including breast, kidney, lung, bone and other soft-tissue indications, depending on local regulatory permissions and clinical practice.

The company is part of a broader medical trend toward focal therapies that seek to treat disease while preserving healthy tissue and improving patient experience. Cryoablation is already an established concept in interventional radiology, and IceCure’s differentiation lies in its compact liquid nitrogen system, disposable probes and focus on expanding use in outpatient or minimally invasive environments.

IceCure operates in a market shaped by clinical evidence, regulatory clearances, reimbursement decisions and physician training. Adoption depends not only on device performance, but also on whether hospitals, surgeons and interventional radiologists view cryoablation as appropriate for specific patient groups. As a growth-stage device company, IceCure’s prospects are closely linked to commercialization progress, indication expansion and the accumulation of supportive clinical data.